Top

Breast Cancer Research and Treatment

Published in:

01-02-2019 | Letter to the Editor

Clinical implication of E-cadherin deficiency in lobular breast cancer

Authors: Giovanni Corso, Gabriella Pravettoni, Viviana Galimberti, Paolo Veronesi

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Excerpt

We read with high interest the recent results published by Teo and Colleagues [1]. …

Teo K, Gómez-Cuadrado L, Tenhagen M, Byron A, Rätze M, van Amersfoort M et al (2018) E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. Sci Rep 8(1):15454. https://doi.org/10.1038/s41598-018-33525-5 CrossRefPubMedPubMedCentral

Christofori G, Semb H (1999) The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 24(2):73–76CrossRefPubMed

Takeichi M (1993) Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 5(5):806–811CrossRefPubMed

Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R et al (2013) Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 31(7):868–875. https://doi.org/10.1200/JCO.2012.44.4612 CrossRefPubMed

Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C et al (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14(24):6107–6115CrossRefPubMedPubMedCentral

Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N et al (2012) Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 133(2):713–723. https://doi.org/10.1007/s10549-012-2002-z CrossRefPubMed

Colleoni M, Russo L, Dellapasqua S (2011) Adjuvant therapies for special types of breast cancer. Breast 20(Suppl 3):S153–S157. https://doi.org/10.1016/S0960-9776(11)70315-0 CrossRefPubMed

Mateus AR, Simões-Correia J, Figueiredo J, Heindl S, Alves CC, Suriano G et al (2009) E-cadherin mutations and cell motility: a genotype-phenotype correlation. Exp Cell Res 315(8):1393–1402. https://doi.org/10.1016/j.yexcr.2009.02.020 CrossRefPubMed

Mateus AR, Seruca R, Machado JC, Keller G, Oliveira MJ, Suriano G et al (2007) EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. Hum Mol Genet 16(13):1639–1647CrossRefPubMed

Title: Clinical implication of E-cadherin deficiency in lobular breast cancer
Authors: Giovanni Corso
Gabriella Pravettoni
Viviana Galimberti
Paolo Veronesi
Publication date: 01-02-2019
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-5051-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2019

Predictive value of lymphoscintigraphy in patients with breast cancer-related lymphedema undergoing complex decongestive therapy

Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals

Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer

Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis

PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer

Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society

Keynote webinar | Spotlight on antibody–drug conjugates in cancer